EBV Reactivation and Long COVID
If you’ve spent time reading about Long COVID, you’ve probably seen Epstein-Barr virus, or EBV, come up. Sometimes it is framed in a confusing way, as if someone might “really have EBV instead of Long COVID.”
That is usually the wrong way to think about it. The more plausible idea is a cascade: SARS-CoV-2 disrupts the immune system, latent viruses such as EBV become harder to contain, and that added immune activity may worsen symptoms in some people.
What EBV Is
Epstein-Barr virus is one of the most common viruses on earth. Roughly 90-95% of adults have been infected. Many people never notice the initial infection. Others develop infectious mononucleosis, or “mono,” and feel intensely sick for weeks.
Like other herpesviruses, EBV never fully leaves the body. After the initial infection, it becomes latent, meaning it persists quietly inside cells, especially B cells. Your immune system does not eliminate EBV; it keeps it under control.
For most people, that control works well. EBV may occasionally shed or stir without causing obvious illness. The concern in Long COVID is that SARS-CoV-2 may weaken or distort that immune control enough for EBV activity to become more clinically relevant.
What “Reactivation” Means
Reactivation means a latent virus becomes biologically active again. This is not unique to COVID. EBV and other herpesviruses can reactivate during major immune stress, including severe illness, immunosuppression, critical illness, and some chronic infections.
The Long COVID hypothesis is that SARS-CoV-2 can throw the immune system off balance enough to let dormant EBV become active again. Once active, EBV may add more immune stimulation and inflammation, potentially contributing to symptoms such as fatigue, brain fog, sore throat, swollen glands, pain, or post-exertional worsening.
So the idea is not “EBV instead of Long COVID.” It is “COVID may trigger immune dysfunction, and EBV reactivation may be one downstream part of that dysfunction.”
A similar pattern is sometimes discussed with shingles, which is reactivation of varicella-zoster virus, the virus that causes chickenpox. The common thread is immune control being disrupted.
Why Researchers Are Interested
The association between EBV markers and Long COVID has appeared repeatedly.
One early study found that about two-thirds of people with Long COVID had antibody markers suggesting recent EBV reactivation, compared with about 10% of controls. The same study found that higher EBV early-antigen antibody levels correlated with more Long COVID symptoms.
Other work points in a similar direction. A 2023 study found EBV DNA in throat washings from 50% of Long COVID fatigue patients, compared with 20% of recovered controls. A 2025 case-control study found EBV reactivation in 28.6% of post-COVID patients with persistent fatigue, compared with 11.3% of recovered controls.
A larger JCI study also found that markers suggesting recent EBV reactivation were independently associated with fatigue, while high EBNA IgG levels were associated with neurocognitive symptoms. Importantly, that study also found Long COVID in people without evidence of EBV reactivation, which means EBV is not required for Long COVID to happen.
What the Evidence Does and Does Not Prove
The evidence supports a real association. It does not prove that EBV is the main cause of Long COVID.
There are two possibilities that are hard to separate. EBV reactivation might directly contribute to symptoms in some patients. Or EBV reactivation might simply be a marker of the same immune disruption that is already causing Long COVID. Both could be true in different people.
A 2025 laboratory study adds another caution. It found that EBV reactivation in Long COVID does not appear to result from a simple direct mechanism in which SARS-CoV-2 infects the relevant EBV-harboring cells and flips EBV back on. That points toward a more indirect immune-mediated process, which fits the broader picture: this is a messy immune cascade, not a simple on/off switch.
Testing Is Tricky
EBV testing can be useful, but it is easy to overinterpret.
A positive VCA IgG or EBNA IgG usually means past infection, which is expected in most adults. High antibody levels can persist for years and do not automatically mean current reactivation. Early antigen IgG can suggest active or recent infection, but the CDC notes that some healthy people can have EA antibodies for years. EBV PCR can detect viral DNA, but a negative blood PCR does not necessarily rule out localized activity in tissues or the throat.
That means EBV labs need to be interpreted by someone who understands the pattern, the timing, and the clinical context.
What About Antivirals?
This is the practical question, and the evidence is still weak.
Acyclovir, valacyclovir, and related drugs can inhibit lytic EBV replication in some settings, and they can reduce EBV shedding. But EBV is mostly latent, and these drugs do not clear latent EBV. In infectious mononucleosis, antivirals have generally reduced viral shedding without reliably improving symptoms.
For Long COVID, there are no large, peer-reviewed randomized trials showing that EBV-directed antivirals treat EBV-associated Long COVID. Small studies, case reports, and ongoing trials are worth watching, including valacyclovir-based combination approaches, but they do not yet establish a standard treatment.
If you've used acyclovir, please consider leaving a review in our database here. If you've used valacyclovir, please consider leaving a review here. If you'd like to find a provider who may prescribe these medications, search our database here.